Specific active immunochemotherapy in lung cancer: a survival study.
A radomized clinical trial of chemotherapy, immunization and immunochemotherapy among 55 patients with stages I and II carcinoma of the lung is reported. The survival rate in the immunized groups was significantly better (P = 0.001) than that in the nonimmunized groups. The results are discussed in the light of the reactivity of the patients to the specific cancer antigen.
D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed; D007167:Immunotherapy; D002955:Leucovorin / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged
D000951:Antigens, Neoplasm; D002955:Leucovorin; D008727:Methotrexate